Latest

Several Factors May Predict Cognitive Decline in Parkinson's Disease

Several Factors May Predict Cognitive Decline in Parkinson's Disease

Dopamine deficiency, decreases in cortical thickness and volume in certain areas of the brain was predictive of cognitive decline.

Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease

Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease

Patients in the treatment group had improved ON and OFF times and no worsening of motor function.

Neurofilament Light Protein Shows Strong Potential as Biomarker for Huntington's Disease

Neurofilament Light Protein Shows Strong Potential as Biomarker for Huntington's Disease

Investigators examined blood plasma samples taken annually from a cohort of 201 huntingtin gene (HTT) carriers.

Risk for Death Significantly Increased in Patients With Synucleinopathies

Risk for Death Significantly Increased in Patients With Synucleinopathies

Patients with multiple system atrophy with parkinsonism face the greatest risk for death among synucleinopathies.

No Link Between Parkinson's, Overall Vagotomy

No Link Between Parkinson's, Overall Vagotomy

However, there is a trend toward lower risk of Parkinson's for patients with truncal vagotomy.

MRI-Guided Focused Ultrasound More Cost Effective Treatment for Essential Tremor

MRI-Guided Focused Ultrasound More Cost Effective Treatment for Essential Tremor

MRI-guided focused ultrasound thalamotomy is more effective than deep brain stimulation and significantly cheaper.

Electroconvulsive Therapy May Benefit Patients With Huntington's Disease

Electroconvulsive Therapy May Benefit Patients With Huntington's Disease

Electroconvulsive therapy might be safe and reliable therapy for treatment of psychiatric symptoms in patients with Huntington Disease

Treating Tardive Dyskinesia in Schizophrenia

Treating Tardive Dyskinesia in Schizophrenia

Long-term valbenazine may be beneficial in managing tardive dyskinesia in schizophrenia.

What to Expect: International Congress of Parkinson's Disease and Movement Disorders 2017

What to Expect: International Congress of Parkinson's Disease and Movement Disorders 2017

Learn more about what to expect from this year's International Congress of Parkinson's Disease and Movement Disorders.

Treating Tardive Dyskinesia Without Disrupting Psychiatric Treatment

Treating Tardive Dyskinesia Without Disrupting Psychiatric Treatment

Joohi Jimenez-Shahed, MD, discusses her research on the use of deutetrabenazine for the treatment of tardive dyskinesia in patients taking concomitant antipsychotics or neuroleptics. Scroll below the video for the full transcript.

Sign Up for Free e-newsletters